Research partners are chosen on specifics AI tends to drop
Buyers choosing a contract research organisation care about precise things: therapeutic-area experience, study types, regulatory track record, and the regions where a CRO has run trials. These are exactly the specific details that generic capability language tends to bury — and that AI models therefore fail to represent when a buyer asks a targeted question.
Illustrative before
“We are a full-service CRO offering a comprehensive range of clinical research services to clients worldwide, with an experienced team dedicated to quality and timely delivery.”
This describes a CRO in terms that could apply to almost any CRO. There is no therapeutic area, no study type, no regulatory context. Asked to recommend a CRO with, say, bioequivalence experience in a specific therapeutic area, an AI model has nothing here to match against the query.
Illustrative after
“We specialise in bioequivalence and early-phase clinical studies in [named therapeutic areas], with [number] studies completed and experience supporting US-FDA and EU regulatory submissions. Our trials have been conducted across [named regions].”
Now the CRO’s real specialisation is explicit and matchable. When a buyer asks an AI model for a CRO with bioequivalence experience in a particular therapeutic area and a track record of FDA submissions, this organisation can be surfaced accurately — because the facts the buyer is filtering on are present and unambiguous.
Why this matters commercially
For CROs, being described generically is commercially expensive: it means being invisible to precisely the buyers whose needs you are best suited to meet. Making therapeutic and regulatory specialisation legible to AI is what lets a specialist CRO be recommended for the specialist work it actually wins.